Entyvio effective in pediatric IBD, ‘should be included in our treatment paradigm’

WASHINGTON — Entyvio is “safe and effective” for maintaining sustained steroid-free remission at 1 year in children with inflammatory bowel disease, more so in those with ulcerative colitis vs. Crohn’s disease, according to a researcher.
“We know that children with inflammatory bowel disease, compared to adults, can have a more severe disease phenotype that is refractory to conventional therapies,” Ronen E. Stein, MD, a gastroenterologist at Children’s Hospital of Philadelphia and assistant professor of clinical pediatrics at University of Pennsylvania

WASHINGTON — Entyvio is “safe and effective” for maintaining sustained steroid-free remission at 1 year in children with inflammatory bowel disease, more so in those with ulcerative colitis vs. Crohn’s disease, according to a researcher.
“We know that children with inflammatory bowel disease, compared to adults, can have a more severe disease phenotype that is refractory to conventional therapies,” Ronen E. Stein, MD, a gastroenterologist at Children’s Hospital of Philadelphia and assistant professor of clinical pediatrics at University of Pennsylvania